FDA's Biosimilar Labeling Stance Spurs Preemption Questions
Executive Summary
Whether a biosimilar sponsor may unilaterally make safety-related labeling changes is unclear in light of FDA's decision to require labeling for Sandoz's Zarxio that is almost identical to reference product.
You may also be interested in...
FDA Proposes Unilateral Generic Drug Label Changes, Signaling End To Liability Shield
FDA proposed rule would allow ANDA holders to unilaterally make label changes prior to FDA’s approval; NDA and other ANDA holders would have 30 days to revise their labels once FDA approves the change.
Supreme Court Strengthens Generic Liability Shield; FDA Reg Change Could Create Opening
The high court rules 5-4 that generic drug makers cannot be sued for alleged design defects based on the adequacy of a drug’s label warnings; FDA continues to discuss revising its regulations to allow generic companies to change their labeling.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.